» Articles » PMID: 31471970

Toward a Robust Tool for Pharmacokinetic-based Personalization of Treatment with Tacrolimus in Solid Organ Transplantation: A Model-based Meta-analysis Approach

Overview
Specialty Pharmacology
Date 2019 Sep 1
PMID 31471970
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: The objective of this study is to develop a generic model for tacrolimus pharmacokinetics modelling using a meta-analysis approach, that could serve as a first step towards a prediction tool to inform pharmacokinetics-based optimal dosing of tacrolimus in different populations and indications.

Methods: A systematic literature review was performed and a meta-model developed with NONMEM software using a top-down approach. Historical (previously published) data were used for model development and qualification. In-house individual rich and sparse tacrolimus blood concentration profiles from adult and paediatric kidney, liver, lung and heart transplant patients were used for model validation. Model validation was based on successful numerical convergence, adequate precision in parameter estimation, acceptable goodness of fit with respect to measured blood concentrations with no indication of bias, and acceptable performance of visual predictive checks. External validation was performed by fitting the model to independent data from 3 external cohorts and remaining previously published studies.

Results: A total of 76 models were found relevant for meta-model building from the literature and the related parameters recorded. The meta-model developed using patient level data was structurally a 2-compartment model with first-order absorption, absorption lag time and first-time varying elimination. Population values for clearance, intercompartmental clearance, central and peripheral volume were 22.5 L/h, 24.2 L/h, 246.2 L and 109.9 L, respectively. The absorption first-order rate and the lag time were fixed to 3.37/h and 0.33 hours, respectively. Transplanted organ and time after transplantation were found to influence drug apparent clearance whereas body weight influenced both the apparent volume of distribution and the apparent clearance. The model displayed good results as regards the internal and external validation.

Conclusion: A meta-model was successfully developed for tacrolimus in solid organ transplantation that can be used as a basis for the prediction of concentrations in different groups of patients, and eventually for effective dose individualization in different subgroups of the population.

Citing Articles

Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools.

Hoffert Y, Dia N, Vanuytsel T, Vos R, Kuypers D, Van Cleemput J Clin Pharmacokinet. 2024; 63(10):1407-1421.

PMID: 39304577 DOI: 10.1007/s40262-024-01414-y.


Population pharmacokinetic analyses of tacrolimus in non-transplant patients: a systematic review.

Wang C, Zhang Y, Zhao M, Zhao L Eur J Clin Pharmacol. 2023; 79(7):897-913.

PMID: 37261481 DOI: 10.1007/s00228-023-03503-6.


Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective.

Briki M, Andre P, Thoma Y, Widmer N, Wagner A, Decosterd L Pharmaceutics. 2023; 15(4).

PMID: 37111768 PMC: 10147065. DOI: 10.3390/pharmaceutics15041283.


Predictive Performance of Published Tacrolimus Population Pharmacokinetic Models in Thai Kidney Transplant Patients.

Methaneethorn J, Lohitnavy M, Onlamai K, Leelakanok N Eur J Drug Metab Pharmacokinet. 2021; 47(1):105-116.

PMID: 34817826 DOI: 10.1007/s13318-021-00735-8.


Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations.

Henin E, Govoni M, Cella M, Laveille C, Piotti G Adv Ther. 2021; 38(10):5317-5332.

PMID: 34515977 DOI: 10.1007/s12325-021-01905-5.


References
1.
Sikma M, van Maarseveen E, van de Graaf E, Kirkels J, Verhaar M, Donker D . Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. Am J Transplant. 2015; 15(9):2301-13. DOI: 10.1111/ajt.13309. View

2.
Han N, Yun H, Hong J, Kim I, Ji E, Hong S . Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2012; 69(1):53-63. DOI: 10.1007/s00228-012-1296-4. View

3.
Staatz C, Willis C, Taylor P, Lynch S, Tett S . Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003; 9(2):130-7. DOI: 10.1053/jlts.2003.50023. View

4.
Oteo I, Lukas J, Leal N, Suarez E, Valdivieso A, Gastaca M . Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol. 2012; 69(1):65-74. DOI: 10.1007/s00228-012-1300-z. View

5.
Prytula A, Cransberg K, Bouts A, van Schaik R, de Jong H, de Wildt S . The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Clin Pharmacokinet. 2016; 55(9):1129-43. DOI: 10.1007/s40262-016-0390-7. View